Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
A government shutdown, ongoing tensions with China and concerns about continued economic growth have marked the beginning of 2019. Against this backdrop, diagnostic deals continue to move forward. Here’s a quick overview of the past month’s activity. M&A The biggest M&A deal for the period involved Luminex, which has completed its previously announced acquisition of MilliporeSigma’s flow cytometry portfolio. Valued at $75 million in stock, assets, and inventory, it gives Luminex access to Amnis imaging flow cytometry products for cell-based analysis, as well as the Guava portfolio of products, which leverage microcapillary technology and are also used for cell-based analysis. These additions complement Luminex’s offerings and enhance its current flow-based systems—and expand the number of the company’s installed systems to more than 5,000. Other deals that closed this period include two involving OraSure Technologies, and the acquisition of Connective Tissue Gene Tests by Health Network Laboratories. Details for these and other M&As are provided in the chart below. Strategic Alliances Among new strategic alliances is a partnership between population genomics technology company Color and NorthShore University HealthSystem. Together, they have launched an initiative called DNA10K, which will provide genetic testing to 10,000 patients as part of their annual exam with […]
A government shutdown, ongoing tensions with China and concerns about continued economic growth have marked the beginning of 2019. Against this backdrop, diagnostic deals continue to move forward. Here's a quick overview of the past month's activity.
M&A
The biggest M&A deal for the period involved Luminex, which has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio. Valued at $75 million in stock, assets, and inventory, it gives Luminex access to Amnis imaging flow cytometry products for cell-based analysis, as well as the Guava portfolio of products, which leverage microcapillary technology and are also used for cell-based analysis. These additions complement Luminex's offerings and enhance its current flow-based systems—and expand the number of the company's installed systems to more than 5,000.
Other deals that closed this period include two involving OraSure Technologies, and the acquisition of Connective Tissue Gene Tests by Health Network Laboratories. Details for these and other M&As are provided in the chart below.
Strategic Alliances
Among new strategic alliances is a partnership between population genomics technology company Color and NorthShore University HealthSystem. Together, they have launched an initiative called DNA10K, which will provide genetic testing to 10,000 patients as part of their annual exam with their primary care practitioner. The program is aimed at helping patients learn about their genetic makeup, including risk factors for certain disease types such as common hereditary cancers and heart diseases, so that NorthShore may then personalize care for each patient to support improved outcomes, prevention, and overall health. The initiative is the largest known primary-care based genomics program in the United States.
Other U.S. agreements include three involving Personal Genome Diagnostics (PGDx), all of which are detailed in the chart below.
Product integration and deals are likewise hot in Asia this month, especially in China, where, as in the U.S., the focus is often on genomics and/or cancer.
Here's a summary of key diagnostic deals from late December through January:
| MERGERS, ACQUISITIONS & ASSET SALES | ||
| Acquiring Company | Target(s) | Deal Summary |
| Luminex | MilliporeSigma |
|
| OraSure Technologies | CoreBiome |
|
| OraSure Technologies | Novosanis |
|
| Health Network Laboratories | Connective Tissue Gene Tests |
|
| Qiagen | N-of-One |
|
| Chiral Technologies | Arbor Biosciences |
|
| Neogen | Delta Genomics Centre |
|
| STRATEGIC ALLIANCES, PARTNERSHIPS & COLLABORATIONS | ||
| Partner 1 | Partner 2 | Deal Summary |
| Roche | Phoenix Molecular Designs |
|
| Luminex | AllerGenis |
|
| Illumina | PierianDx |
|
| Veracyte | Johnson & Johnson Innovation |
|
| Color | NorthShore University HealthSystem |
|
| Personal Genome Diagnostics (PGDx) | PathGroup |
|
| Personal Genome Diagnostics (PGDx) | Merck |
|
| Personal Genome Diagnostics (PGDx) | KingMed Diagnostics |
|
| Sphere Fluidics | Peak Analysis and Automation (PAA) |
|
| BC Platforms | MedEngine |
|
| Adaptive Biotechnologies | Genentech (part of Roche) |
|
| Arbor Biotechnologies | Vertex Pharmaceuticals |
|
| CellMax Life | Medigen Biotech |
|
| NX Prenatal | Milu Labs |
|
| LifeMap Sciences | Novogene |
|
| Pillar Biosciences | China Biotech Services Holdings |
|
| Biocartis | Nichirei Bioscience |
|
| DISTRIBUTION, SALES & MARKETING AGREEMENTS | ||
| Property Owner | Distributor | Deal Summary |
| Gemelli Biotech | Advanced Medical German |
|
| SpeeDx | AB Analitica |
|
| SpeeDx | Immuno Diagnostic Oy |
|
| Sienna Cancer Diagnostics | Mirax |
|
| Omni Life Science | Bioké |
|
| Roche | MilliporeSigma |
|
| Paragon Genomics | MGI Tech |
|
| LICENSES | ||
| Licensor | Licensee | Deal Summary |
| Salisbury NHS Foundation Trust | NimaGen |
|
| Expedeon | Cell Guidance Systems |
|
| Genfit | Covance (LabCorp drug development business) |
|
| SUPPLY, SERVICE & TESTING AGREEMENTS | ||
| Supplier/Servicer | Client/User | Deal Summary |
| Abbott | Japanese Red Cross Society |
|
| LabCorp | Texas Association of Community Health Centers (TACHC) |
|
| Primerdesign (molecular testing division of Novacyt) | Genesis Diagnostics |
|
Subscribe to view Essential
Start a Free Trial for immediate access to this article